greeksoup/ stock research
Stock research / United States / VTRS · Pharmaceutical Preparations · Nasdaq

Viatris Inc. (VTRS)

Viatris is a global healthcare company supplying medicines to approximately 1 billion patients around the world each year. It operates in more than 165 countries and territories with more than 30,000 employees, has 27 manufacturing, packaging and distribution sites and more than 1,400 approved molecules. The company describes its portfolio as generics including complex products, globally recognised iconic brands, and an expanding portfolio of innovative medicines. It is headquartered in the United States, with global centres in Pittsburgh, Pennsylvania, Shanghai, China and Hyderabad, India.

Viatris Inc.

Viatris is a global healthcare company supplying medicines to approximately 1 billion patients around the world each year. It operates in more than 165 countries and territories with more than 30,000 employees, has 27 manufacturing, packaging and distribution sites and more than 1,400 approved molecules. The company describes its portfolio as generics including complex products, globally recognised iconic brands, and an expanding portfolio of innovative medicines. It is headquartered in the United States, with global centres in Pittsburgh, Pennsylvania, Shanghai, China and Hyderabad, India.

How the company came to exist

Upjohn was incorporated in Delaware on 14 February 2019 as a wholly owned subsidiary of Pfizer, holding the Upjohn Business, which was a primarily off-patent branded and generic established medicines business with 20 legacy oral solid dose brands including Lyrica, Lipitor, Celebrex and Viagra. On 16 November 2020 Upjohn, Mylan and Pfizer combined Mylan with that business through a Reverse Morris Trust transaction; Upjohn became the parent of the combined business and renamed itself Viatris, and Mylan ceased to exist as a separate legal entity. Mylan itself was founded in 1961, became publicly traded in 1973 and grew by acquisition, taking in Matrix Laboratories and Merck KGaA's generic and specialty pharmaceutical business in 2007, Abbott Laboratories' non-U.S. developed markets specialty and branded generics business in 2015 and Meda in 2016.

What has been sold since

Four transactions have narrowed the company. In November 2022 the biosimilars portfolio went to Biocon Biologics for cash and stock, leaving Viatris with a stake of approximately 12.9% on a fully diluted basis. In March 2024 the women's healthcare business, mainly oral and injectable contraceptives, went to Insud Pharma, with two manufacturing plants in India. In June 2024 the active pharmaceutical ingredient business in India went to Matrix Pharma, taking three manufacturing sites and a research lab in Hyderabad and three sites in Vizag, though Viatris kept some research capability in that area. In July 2024 the over-the-counter business went to Cooper Consumer Health, with two plants in France and Italy and a research site in Monza, while Viatris retained the rights to Viagra, to Dymista and to selected over-the-counter products in certain markets.

Four segments, organised by geography

Developed Markets covers North America and Europe. In the United States, where the company describes itself as one of the largest providers of prescription medicines, competition turns on development, timely approval, manufacturing and supply chain, formulary placement, product quality, marketing, portfolio size, customer service, reputation and price, and the customer base, though extensive, comes down to a small number of very large firms. In Europe, governments largely regulate prices or reimbursement levels. Products here include Lyrica, Lipitor, Creon, Breyna, Influvac, Wixela Inhub, the EpiPen Auto-Injector, Fraxiparine and Yupelri.

Greater China covers mainland China, Taiwan and Hong Kong, and the portfolio there is predominantly branded products that have lost exclusivity, with Lipitor, Norvasc and Viagra named. The volume-based procurement policy for such molecules is in its seventh year and covers approximately 490 molecules, all major Viatris brands among them, and the company has rebalanced towards retail pharmacy and e-commerce channels while keeping its hospital presence.

JANZ is Japan, Australia and New Zealand, where pricing is regulated by the national health insurance system in Japan and by the pharmaceutical benefits scheme in Australia, and where selling runs primarily through wholesalers. Products include AMITIZA, EFFEXOR, Lipacreon, Lyrica and the EpiPen Auto-Injector. Emerging Markets covers more than 125 countries across Asia, Africa, Eastern Europe, Latin America and the Middle East, and includes the antiretroviral franchise.

The pipeline

The company points to its record of first approvals of generic versions of Advair Diskus, sold as Wixela Inhub, Restasis, Symbicort, sold as Breyna, and Venofer. It is working on patent-protected assets including selatogrel and cenerimod, on 505(b)(2) products such as a fast-absorbing meloxicam for acute pain and a low dose weekly estrogen patch for contraception, and on being first to market with generics of Abilify Maintena, Injectafer, Ozempic and Wegovy. In Japan the filing names Nefecon, for immunoglobulin A nephropathy, and pitolisant, a histamine H3 receptor agonist for excessive daytime sleepiness in narcolepsy and in obstructive sleep apnea syndrome, among its pipeline assets.

From Viatris' annual report on Form 10-K for the year ended 31 December 2025. The filing

Compare with another name What $10,000 in Viatris became

Latest results

Latest quarterQ3 FY2026ended 30 September 2026 · 10-Q filed 5 November 2026
Revenue
$3.7 billion
-0.3% on the year · -0.2% on the quarter
Q4 FY2024Q3 FY2026
Net income
-$325 million
Q4 FY2024Q3 FY2026
Diluted EPS
-$0.28
Q4 FY2024Q3 FY2026

this quarterthe same quarter a year earlierHover a bar for its figure.

Read the Q3 FY2026 results →the 10-Q on EDGAR ↗
Last full yearFY2025ended 31 December 2025 · 10-K filed 26 February 2026
Revenue
$14.3 billion
-3.0% on the year
FY2018FY2025
Net income
-$3.5 billion
FY2018FY2025
Diluted EPS
-$3.00
FY2018FY2025

this yearthe year beforeHover a bar for its figure.

The years before, in wordsViatris (VTRS) reported revenue of $14.3 billion for fiscal 2025, the year ended 31 December 2025, down 3.0% on the year before. Net loss was $3.5 billion and the diluted loss per share $3.00. Revenue was $14.7 billion in fiscal 2024, $15.4 billion in fiscal 2023, $16.3 billion in fiscal 2022 and $17.9 billion in fiscal 2021. Net income in the same years was a loss of $634 million, $55 million, $2.1 billion and a loss of $1.3 billion. Over the twelve months to 30 September 2026, Viatris reported revenue of $14.7 billion and net loss of $608 million. Revenue grew 3.7% a year, compounded, over the five years to fiscal 2025. Viatris declared $0.48 a share in dividends over the last four quarters and had 1.15 billion shares outstanding at the latest filed count. At 30 September 2026 it carried $13.3 billion of debt and $1.8 billion of cash. At the close of 6 November 2026 the market cap of Viatris was $22.8 billion.
Read the FY2025 results →the 10-K on EDGAR ↗

Ratios

From the filings

ROE-4.4%
ROCE-0.0%
Operating margin-0.0%
Net margin-4.1%
FCF margin14.3%
Interest cover-0.01x
Debt to equity0.97x
Cash conversionn/a
Share count, last 12 months-0.5%
Sales CAGR, 3 years-4.2%
Profit CAGR, 3 yearsn/a
EPS, TTM-$0.53

At the close of 6 November 2026

Price$19.92
Market cap$22.8 billion
Stock P/En/a
Price to book1.7x
EV / EBITDA12.2x
Dividend yield2.4%
Market cap / sales1.6x
52-week high$19.92
52-week low$10.11
Price, 1 year97.0%
Price CAGR, 3 years29.7%
Price CAGR, 5 years7.7%

29 ready-made ratios, from FCF yield to net debt to EBITDA, wait on the Formulas page, each with what it tells you. Browse and add them →

Worked from the filed figures; hover a name for the formula.
Read moreThe priced ones use the latest price, the last regular-hours trade on IEX. Debt to equity here stands on long-term debt as Viatris Inc. files it, with lease liabilities counted separately and never inside it. Nothing here is a valuation or a view.
VTRSgreeksoup.ai
Daily prices to 6 November 2026, adjusted for splits; from 28 September 2026 each day's price is the last regular-hours trade on IEX.
Read moreData provided for free by IEX. By accessing or using IEX Historical Data, you agree to the IEX Historical Data Terms of Use. Day by day for the last three years; before that one point a week, carrying the week's last close and its average daily volume, so a volume bar means the same thing across the whole series; the bars sit under the price on their own scale, on the right. The moving averages need consecutive days and are drawn from the daily part. P/E is the close over the trailing four quarters' EPS as filed at each filing date, on the current share count; the dashed line is the median over the range shown. Sales and margin are quarterly revenue and the operating margin from the tables above. EV/EBITDA, price to book and market cap to sales use the latest filed balance sheet and share count at each date. Before the quarters on file begin, P/E, price to book and market cap to sales stand on each annual report from the day it was filed. Drawn in your browser; the range and overlay you pick are remembered here only.

Quarterly results

Q4 FY2021 *Q1 FY2022Q2 FY2022Q3 FY2022Q4 FY2022 *Q1 FY2023Q2 FY2023Q3 FY2023Q4 FY2023 *Q1 FY2024Q2 FY2024 †Q3 FY2024Q4 FY2024 *Q1 FY2025Q2 FY2025Q3 FY2025Q4 FY2025 *Q1 FY2026Q2 FY2026Q3 FY2026
Revenue4,3424,1924,1174,0783,8763,7293,9193,9423,8373,6633,7973,7513,5283,2543,5823,7603,7043,5173,7573,750
Cost of revenue2,7952,4202,4142,3302,6022,1872,3102,2512,2412,1592,3512,2922,3132,0932,2492,3882,5562,3602,3002,312
Gross profit1,5461,7711,7031,7481,2741,5421,6091,6911,5961,5041,4451,4591,2151,1611,3331,3721,1481,1571,4561,438
Gross margin36%42%41%43%33%41%41%43%42%41%38%39%34%36%37%36%31%33%39%38%
R&D267142163175n/a183208211n/a200204198206222219250275249248232
SG&A1,0839159811,0171,2659591,0321,0541,6061,0181,0371,0031,0479489298871,0319291,134951
Operating income-77.6707549560-201400369452-454204-240226-180-2,882233179-193-79.76.3262
Operating margin-2%17%13%14%-5%11%9%11%-12%6%-6%6%-5%-89%7%5%-5%-2%0%7%
Interest expense148146146153147147144142141138146146120116117120120120121112
Pre-tax income-2045283894281,469323333402-855205-39290.5-526-3,097-217-7.9-343-247-64.0128
Tax raten/a24%19%17%31%30%21%18%n/a44%n/a-5%n/an/an/an/an/an/an/a354%
Net income-2643993143541,011225264332-766114-32694.8-516-3,042-4.6-128-340176-119-325
Net margin-6%10%8%9%26%6%7%8%-20%3%-9%3%-15%-93%-0%-3%-9%5%-3%-9%
Diluted EPS-$0.22$0.33$0.26$0.29$0.83$0.19$0.22$0.27-$0.64$0.09-$0.27$0.08-$0.43-$2.55$0.00-$0.11-$0.30$0.15-$0.10-$0.28
Operating cash flow5231,138802869143971515834479615379826483536220745816388382899
Capital expenditure19764.583.910415447.867.895.916649.858.877.014042.652.986.819639.952.885.7
Free cash flow3261,074719765-11.1923447738314565320750342493167658619348329814
Buybacksn/a0.00.00.00.02500.00.00.02500.00.00.017517567.982.20.0150150
Shares outstanding1,210m1,212m1,213m1,213m1,197m1,199m1,200m1,200m1,188m1,191m1,194m1,194m1,194m1,174m1,166m1,152m1,151m1,165m1,149m1,146m
Filing10-K10-Q10-Q10-Q10-K10-Q10-Q10-Q10-K10-Q10-Q10-Q10-K10-Q10-Q10-Q10-K10-Q10-Q10-Q
Each quarter as filed, linked to its filing.
Read more* The fourth quarter is the full year less the first three quarters, because the company files the year and not the quarter on its own. A fourth quarter's EPS, and its diluted share count where shown, are from the company's results press release for that quarter, checked against the company's filed figures or a second data source. A quarter marked † is shown as the company last restated it in a later filing, so it compares with the quarters around it on one basis; rest on a figure for the one first filed. EPS is as filed. Money is in $ million as the company files it, or in $ billion by the switch above the tables; per share figures and the share count are as they are. Free cash flow is operating cash flow less capital expenditure; the effective tax rate is income tax over pre-tax income; margins are the line over revenue. Gross profit is revenue less cost of revenue, and operating income is revenue less the company's own total costs, where the statement does not print those lines. Cash flow lines filed year to date are the difference between two filings. Shares outstanding are at the period end where the balance sheet tags them, otherwise the count on the filing's cover page. A derived fourth-quarter EPS is left blank when a split in the year makes the arithmetic meaningless.

Income statement (profit and loss)

FY2018FY2019 †FY2020FY2021FY2022 †FY2023 †FY2024 †FY2025TTM
Revenue11,43411,50011,94617,88616,26315,42714,73914,30014,727
Cost of revenue7,4327,6038,14912,3119,7668,9889,1169,2869,527
Gross profit4,0023,8983,7975,5766,4976,4395,6245,0145,200
Gross margin35.0%33.9%31.8%31.2%40.0%41.7%38.2%35.1%35.3%
Research and development7046405557516628058099661,003
Selling, general and administrative2,4412,5643,3454,5294,1794,0704,1053,7944,045
Operating income906716-211-34.01,61576610.1-2,663-4.6
Operating margin7.9%6.2%-1.8%-0.2%9.9%5.0%0.1%-18.6%-0.0%
Interest expense542517498636592573550471473
Pre-tax income298154-721-6642,813203-623-3,665-526
Income tax-54.1138-51.360573514811.0-15081.4
Effective tax rate-18.1%89.1%n/an/a26.1%73.0%n/an/an/a
Net income35216.8-670-1,2692,07954.7-634-3,515-608
Net margin3.1%0.1%-5.6%-7.1%12.8%0.4%-4.3%-24.6%-4.1%
Diluted EPS$0.68$0.03-$1.11-$1.05$1.71$0.05-$0.53-$3.00-$0.53
Filing10-K10-K10-K10-K10-K10-K10-K10-K
From each year's 10-K, linked; TTM is the last four quarters.
Read moreFree cash flow is operating cash flow less capital expenditure; the effective tax rate is income tax over pre-tax income; margins are the line over revenue. Gross profit is revenue less cost of revenue, and operating income is revenue less the company's own total costs, where the statement does not print those lines. Those four are arithmetic on the filed numbers; everything else is as filed. Money is in $ million as the company files it, or in $ billion by the switch above the tables; per share figures and share counts are as they are. † The year as the company last restated it in a later filing; rest on a figure for the one first filed. EPS is as filed.

Revenue by segment FY2018 to FY2025

FY2018FY2019FY2020FY2021FY2022FY2023FY2024FY2025Share
of the parts, latest year
Developed Markets8,2898,2408,51110,4299,7919,2788,9618,55259.8%
Greater China1682152602,2132,2012,1602,1682,33216.3%
Emerging Markets1,6791,7231,8543,1452,6372,5632,2602,21815.5%
JANZ1,1331,1921,1952,0271,6341,4261,3501,1988.4%
Developed MarketsGreater ChinaEmerging MarketsJANZ
11.3FY201811.4FY201911.8FY202017.8FY202116.3FY202215.4FY202314.7FY202414.3FY2025

$ billion; hover a block for its figure and share

From the company's 10-Ks, in its own words (latest 10-K).
Read moreEach year's figures come from the most recent 10-K that includes that year. A year is shown only where the parts add up to the revenue above. Fiscal years are labelled by the year they end in.

Profit by segment FY2018 to FY2023

The operating profit each segment reports. Costs Viatris does not charge to a segment are left out, so the segments can add up to more than the company's own operating profit.

FY2018FY2019FY2020FY2021FY2022FY2023Margin
FY2023
Developed Markets4,2704,1374,2445,1434,8784,08644.0%
Emerging Markets6475626101,4021,2071,09242.6%
Greater China71.989.952.71,3971,5121,42766.0%
JANZ36332336576266652336.7%
Developed MarketsGreater ChinaEmerging MarketsJANZ
5,352FY20185,112FY20195,272FY20208,705FY20218,263FY20227,128FY2023

$ million; the figure over a bar is all the segments together. Hover a block for its profit, sales and margin.

FY2023Share of salesShare of profit
Developed Markets60%57%
Emerging Markets17%15%
Greater China14%20%
JANZ9%7%

Each column adds to 100%. A segment with a bigger share of the profit than of the sales makes more on each dollar it sells.

From the company's 10-Ks, in its own words (latest 10-K).
Read moreEach year's figures come from the most recent 10-K that includes that year. A year is shown only where every segment with sales that year has an operating profit figure. A margin is a segment's operating profit over its own sales.

Revenue by product or service FY2018 to FY2025

FY2018FY2019FY2020FY2021FY2022FY2023FY2024FY2025Share
of the parts, latest year
Brands5,5245,3625,23510,8419,8909,8009,2009,18464.4%
Generics5,2224,7975,2906,9726,3285,5885,4925,06635.6%
Complex Gx and Biosimilars5231,2111,296n/an/an/an/an/an/a
BrandsGenericsComplex Gx and Biosimilars FY2018 to FY2020
11.3FY201811.4FY201911.8FY202017.8FY202116.2FY202215.4FY202314.7FY202414.3FY2025

$ billion; hover a block for its figure and share; a part named with years is one the company split its revenue into only then

From the company's 10-Ks, in its own words (latest 10-K).
Read moreEach year's figures come from the most recent 10-K that includes that year. A year is shown only where the parts add up to the revenue above. Fiscal years are labelled by the year they end in.

Cash flow

FY2018FY2019 †FY2020FY2021FY2022 †FY2023 †FY2024 †FY2025TTM
Operating cash flow2,3421,8041,2323,0172,9992,9002,3032,3162,485
Capital expenditure252213243457406377326379375
Free cash flow2,0901,5909892,5602,5932,5231,9771,9372,110
Free cash flow margin18.3%13.8%8.3%14.3%15.9%16.4%13.4%13.5%14.3%
Cash from investing-1,210-525-301-1181,474-8641,801-428307
Cash from financing-1,091-1,169-606-3,012-3,878-2,302-4,330-1,294-1,973
Depreciation and amortisation2,1102,0192,2164,5063,0282,7402,8932,7982,812
Share-based compensation-3.356.879.2111116181146178176
Buybacks4320.00.00.00.0250250500382
Dividend per sharen/an/an/a$0.33$0.48$0.48$0.48$0.48$0.48
Diluted shares, weighted516m516m601m1,209m1,217m1,207mn/an/a1,149m
Shares outstanding at period endn/a100n/an/an/an/an/an/a1,146m
Filing10-K10-K10-K10-K10-K10-K10-K10-K
Cash paid in the year, from the cash flow statement.
Read moreThe dividend per share is as declared. Diluted shares are the weighted average for the year; a falling count is the buybacks net of issuance. TTM sums the last four quarters; the share counts are the latest quarter's.

Balance sheet

FY2018FY2019 †FY2020FY2021FY2022 †FY2023 †FY2024 †FY2025TTM
Funded by
Shareholders' equity12,167n/a22,95420,49321,07220,46718,63614,71113,686
Non-controlling interestn/a11,884n/an/an/an/an/an/an/a
Short-term borrowingsn/a0.0n/an/a0.0n/an/an/an/a
Debtn/a12,72225,83923,08819,27418,13214,04714,41413,315
Operating lease liabilitiesn/a176230201181165179178154
Other liabilitiesn/a6,47412,53111,0629,4948,9218,6397,8907,529
Total liabilities and equityn/a31,25661,55354,84350,02247,68641,50137,19334,683
Owned
Fixed assetsn/a2,1503,4603,1893,0242,7602,6662,6142,420
Goodwill9,7489,59112,34712,11410,4269,8679,1336,7556,620
Intangible assetsn/a11,65029,68326,13422,60719,18117,07115,10213,080
Investmentsn/a26.839.138.235.337.038.040.7n/a
Trading assetsn/an/a45.851.042.649.355.565.769.9
Cash and equivalents3884768447011,2609927351,3221,789
Receivablesn/a3,0594,8444,2663,8143,7003,2213,0313,121
Inventoryn/a2,6715,4723,9783,5203,4703,8543,9993,829
Other assetsn/a1,6334,8184,3725,2937,6294,7274,2633,754
Total assetsn/a31,25661,55354,84350,02247,68641,50137,19334,683
Filing10-K10-K10-K10-K10-K10-K10-K10-K
At the fiscal year end; the TTM column is the latest quarter end.
Read moreBoth totals are the company's own. Other liabilities is the filed total less the rows above it: payables, deferred revenue, taxes, borrowings the rows above do not carry and the rest; other assets is the same on the other side. Investments add the current and non-current lines as filed. Debt is the company's own stated total where it files one, otherwise its long-term debt with the current maturities, never parts added together. A row is left blank in a year where the lines shown overlap and the remainder would fall below nil.

Compounded growth

10 years5 years3 yearsTTM
Sales growth, compoundedn/a3.7%-4.2%4.3%
Profit growth, compoundedn/an/an/an/a
Return on equity, averagen/a-4.7%-9.0%-23.9%
Yearly growth, compounded; TTM is the last four quarters against the four before.
Read moreReturn on equity is net income over shareholders' equity at each year end, averaged over the window (the TTM column is the latest year alone); equity is the parent's shareholders' equity as tagged in the 10-K. Arithmetic on filed numbers, nothing forecast.

Questions

What was Viatris' revenue in fiscal 2025?

Viatris (VTRS) reported revenue of $14.3 billion for fiscal 2025, the year ended 31 December 2025, down 3.0% on the year before.

How much did Viatris earn in fiscal 2025?

Net loss was $3.5 billion for fiscal 2025, and the diluted loss per share $3.00.

What is Viatris' market cap?

The market cap of Viatris was $22.8 billion at the close of 6 November 2026.

Does Viatris pay a dividend?

Yes. Viatris declared $0.48 a share in dividends over the four quarters to 30 September 2026.

How much debt does Viatris have?

At 30 September 2026 Viatris carried $13.3 billion of debt and $1.8 billion of cash.

Peers: Pharmaceutical Products

CompanyMarket capP/EROEOp. marginSales growth
TTM		Debt to equityDiv. yield
Eli Lilly & Co. LLY$1.27 trillion43.9868.5%n/a45.5%1.230.5%
Johnson & Johnson JNJ$665.0 billion41.8619.7%n/a7.8%0.551.9%
AbbVie Inc. ABBV$514.8 billion50.13n/a32.2%10.7%n/a2.4%
Merck & Co., Inc. MRK$361.8 billion151.295.5%n/a4.9%1.202.3%
Novartis AG NVS *$310.3 billion22.7530.3%n/a8.4%0.622.5%
AstraZeneca PLC AZN *$289.1 billion28.5121.0%23.4%8.6%0.571.7%
Abbott Laboratories ABT$190.5 billion41.039.2%13.8%10.0%0.612.3%
Novo Nordisk A/S NVO *$179.9 billion11.7152.8%41.3%6.4%0.674.4%
Pfizer Inc. PFE$167.5 billion41.984.5%n/a1.3%0.705.9%
Vertex Pharmaceuticals Inc. VRTX$138.7 billion35.1919.0%33.2%10.5%0.22n/a
Bristol-Myers Squibb Co. BMY$127.0 billion13.7839.5%22.6%4.2%1.834.1%
Sanofi SNY *$114.7 billion13.2210.9%n/a6.2%0.264.7%
All 175 in Pharmaceutical Products
CompanyMarket capP/EROEOp. marginSales growth
TTM		Debt to equityDiv. yield
Eli Lilly & Co. LLY$1.27 trillion43.9868.5%n/a45.5%1.230.5%
Johnson & Johnson JNJ$665.0 billion41.8619.7%n/a7.8%0.551.9%
AbbVie Inc. ABBV$514.8 billion50.13n/a32.2%10.7%n/a2.4%
Merck & Co., Inc. MRK$361.8 billion151.295.5%n/a4.9%1.202.3%
Novartis AG NVS *$310.3 billion22.7530.3%n/a8.4%0.622.5%
AstraZeneca PLC AZN *$289.1 billion28.5121.0%23.4%8.6%0.571.7%
Amgen Inc. AMGN$249.0 billion26.7065.4%32.4%8.2%3.762.2%
Gilead Sciences, Inc. GILD$207.1 billionn/a-29.6%-7.6%6.5%2.011.9%
Abbott Laboratories ABT$190.5 billion41.039.2%13.8%10.0%0.612.3%
Novo Nordisk A/S NVO *$179.9 billion11.7152.8%41.3%6.4%0.674.4%
Pfizer Inc. PFE$167.5 billion41.984.5%n/a1.3%0.705.9%
Vertex Pharmaceuticals Inc. VRTX$138.7 billion35.1919.0%33.2%10.5%0.22n/a
Bristol-Myers Squibb Co. BMY$127.0 billion13.7839.5%22.6%4.2%1.834.1%
Sanofi SNY *$114.7 billion13.2210.9%n/a6.2%0.264.7%
Moderna, Inc. MRNA$102.7 billionn/a-40.8%-116.0%13.1%0.52n/a
GSK plc GSK *$101.0 billion13.5334.9%24.3%4.1%1.083.4%
Regeneron Pharmaceuticals, Inc. REGN$95.5 billion19.9714.4%28.8%18.6%0.060.4%
Takeda Pharmaceutical Company Limited TAK *$66.4 billionn/a-2.1%0.1%-1.7%0.663.1%
argenx SE ARGX *$57.4 billion47.4317.6%n/a89.9%0.00n/a
IDEXX Laboratories Inc. IDXX$53.3 billion45.5863.2%32.3%11.9%0.45n/a
Teva Pharmaceutical Industries Ltd. TEVA$49.7 billion99.096.4%8.3%2.7%2.10n/a
Royalty Pharma plc RPRX$37.5 billion44.276.9%57.1%11.4%0.881.4%
Biogen Inc. BIIB$36.7 billion106.201.8%4.3%2.3%0.41n/a
Genmab A/S GMAB *$34.5 billion34.8916.5%28.6%19.2%0.90n/a
Zoetis Inc. ZTS$32.4 billion13.5175.3%n/a1.0%2.742.6%
Roivant Sciences Ltd. ROIV$28.1 billionn/a-6.3%-7,914.8%-67.6%0.00n/a
Insmed Inc. INSM$25.1 billionn/a-83.4%-37.1%240.0%0.76n/a
United Therapeutics Corp. UTHR$23.8 billion21.2119.6%41.4%1.9%0.00n/a
Viatris Inc. VTRS$22.8 billionn/a-4.4%-0.0%4.3%0.972.4%
BioNTech SE BNTX *$22.0 billionn/a-5.9%-49.0%4.3%0.01n/a
Alnylam Pharmaceuticals, Inc. ALNY$20.9 billion8.1075.6%19.5%56.2%0.28n/a
Exelixis, Inc. EXEL$17.0 billion20.8348.3%40.2%9.1%0.00n/a
Neurocrine Biosciences Inc. NBIX$16.7 billion24.4318.1%24.0%38.0%0.00n/a
Jazz Pharmaceuticals plc JAZZ$15.1 billion79.824.9%9.0%13.5%1.33n/a
Kiniksa Pharmaceuticals International, plc KNSA$14.7 billion72.1615.4%13.8%58.2%0.00n/a
BridgeBio Pharma, Inc. BBIO$14.6 billionn/an/a-38.5%167.3%n/an/a
Elanco Animal Health Inc. ELAN$12.9 billionn/a-2.2%n/a12.1%0.52n/a
Dr. Reddy’s Laboratories Limited RDY *$12.4 billion27.5111.4%15.0%3.2%0.210.6%
Halozyme Therapeutics, Inc. HALO$11.8 billion26.38n/a37.4%45.0%n/an/a
Bio-Techne Corp. TECH$11.4 billion66.787.9%19.6%0.9%0.090.4%
Kymera Therapeutics, Inc. KYMR$11.2 billionn/a-21.6%-396.0%133.8%0.00n/a
Biomarin Pharmaceutical Inc. BMRN$10.8 billionn/a-0.3%3.1%18.1%0.67n/a
Repligen Corp. RGEN$9.8 billionn/a-0.6%2.3%13.8%0.27n/a
Madrigal Pharmaceuticals, Inc. MDGL$9.3 billionn/a-24.8%-10.7%92.8%0.54n/a
TG Therapeutics, Inc. TGTX$9.2 billion21.8273.1%17.1%76.1%1.23n/a
ImmunityBio, Inc. IBRX$9.1 billionn/an/a-151.9%192.9%n/an/a
Krystal Biotech, Inc. KRYS$8.9 billion40.8215.7%48.4%26.0%0.00n/a
Protagonist Therapeutics, Inc. PTGX$8.6 billion27.9731.5%58.6%163.7%0.00n/a
Arrowhead Pharmaceuticals, Inc. ARWR$8.2 billionn/a-68.7%-33.8%16.8%1.86n/a
Corcept Therapeutics Inc. CORT$8.0 billion57.2419.5%11.5%30.0%0.00n/a
Rhythm Pharmaceuticals, Inc. RYTM$7.8 billionn/a-220.3%-66.7%61.0%1.17n/a
Alkermes plc. ALKS$7.7 billionn/a-0.0%3.7%15.3%0.81n/a
Twist Bioscience Corp. TWST$7.6 billionn/a-30.7%-33.6%19.2%0.03n/a
Cytokinetics Inc. CYTK$7.5 billionn/an/a-625.2%29.9%n/an/a
Axsome Therapeutics, Inc. AXSM$7.0 billionn/a-149.2%-17.5%54.2%1.78n/a
CG Oncology, Inc. CGON$6.8 billionn/a-24.0%-4,293.5%183.6%0.00n/a
Lantheus Holdings, Inc. LNTH$6.6 billion24.7819.9%18.6%2.4%0.42n/a
Ionis Pharmaceuticals Inc. IONS$6.5 billionn/a-128.5%-68.0%-7.4%3.01n/a
Amneal Pharmaceuticals, Inc. AMRX$6.4 billion41.10476.5%14.6%9.3%80.86n/a
Ligand Pharmaceuticals Inc. LGND$6.1 billion136.655.4%9.5%1.0%1.17n/a
Mirum Pharmaceuticals, Inc. MIRM$6.1 billionn/an/a-133.6%42.2%n/an/a
Scholar Rock Holding Corp. SRRK$5.7 billionn/an/an/an/a0.77n/a
PTC Therapeutics, Inc. PTCT$5.5 billionn/an/a12.8%-35.1%n/an/a
Crispr Therapeutics AG CRSP$4.9 billionn/a-27.7%-2,114.8%-34.3%0.36n/a
Gossamer Bio, Inc. GOSS$4.8 billionn/an/a-311.7%32.4%n/an/a
Travere Therapeutics, Inc. TVTX$4.7 billionn/a-538.0%-20.5%49.4%26.72n/a
Adaptive Biotechnologies Corp. ADPT$4.5 billionn/a-40.0%-16.2%17.9%1.90n/a
Relay Therapeutics, Inc. RLAY$4.1 billionn/a-35.9%-3,094.9%23.9%0.00n/a
Liquidia Corp. LQDA$4.0 billion32.3971.0%37.4%2,233.6%n/an/a
Xenon Pharmaceuticals Inc. XENE$3.8 billionn/a-32.9%n/an/a0.00n/a
Iovance Biotherapeutics, Inc. IOVA$3.7 billionn/a-27.1%-60.8%51.3%0.00n/a
Acadia Pharmaceuticals Inc. ACAD$3.7 billion10.0626.1%10.2%14.8%0.00n/a
AbCellera Biologics Inc. ABCL$3.6 billionn/a-18.4%-340.2%101.3%0.00n/a
Organon & Co. OGN$3.6 billion18.2217.9%n/a-3.2%7.170.6%
Tango Therapeutics, Inc. TNGX$3.6 billionn/a-12.1%-253.4%121.5%0.00n/a
Viking Therapeutics, Inc. VKTX$3.4 billionn/a-106.6%n/an/a0.43n/a
Tarsus Pharmaceuticals, Inc. TARS$3.4 billionn/a-675.0%-102.0%86.3%0.700.0%
Supernus, Inc. INDV$3.3 billion7.88n/a40.6%16.4%n/an/a
DBV Technologies S.A. DBVT$3.3 billionn/a-139.5%-5,420.1%-31.5%0.00n/a
Viridian Therapeutics, Inc. VRDN$3.2 billionn/a-78.1%-1,781.4%-62.8%0.63n/a
Arcutis Biotherapeutics, Inc. ARQT$3.2 billion121.6412.3%6.9%60.0%0.45n/a
Denali Therapeutics Inc. DNLI$3.2 billionn/an/an/an/a0.00n/a
Supernus, Inc. SUPN$3.1 billion9.62n/a45.5%16.2%n/an/a
Bausch Health Companies Inc. BHC$3.1 billionn/an/a11.2%10.8%n/an/a
Ideaya Biosciences, Inc. IDYA$3.0 billionn/an/an/an/a0.00n/a
Adma Biologics, Inc. ADMA$2.8 billion16.5241.6%46.5%6.3%0.45n/a
Silence Therapeutics plc SLN$2.8 billionn/a-155.8%-11,106.8%-97.7%0.00n/a
Vericel Corp. VCEL$2.8 billion85.298.7%8.3%25.3%0.00n/a
Xeris Biopharma Holdings, Inc. XERS$2.8 billionn/a-13.3%12.7%38.4%3.89n/a
Beam Therapeutics Inc. BEAM$2.7 billionn/a-11.2%-267.7%163.3%0.11n/a
Xencor Inc. XNCR$2.7 billionn/a-21.0%-72.7%33.5%0.17n/a
Neogen Corp. NEOG$2.6 billionn/a-2.7%-0.8%-0.3%0.37n/a
Celldex Therapeutics, Inc. CLDX$2.3 billionn/a-47.6%-213,033.8%-94.0%0.00n/a
Arcus Biosciences, Inc. RCUS$2.3 billionn/a-126.5%-475.0%-58.3%0.28n/a
NewAmsterdam Pharma Co. N.V. NAMS$2.3 billionn/a-32.5%-900.1%-26.4%0.00n/a
Schrodinger, Inc. SDGR$2.2 billionn/a-19.6%-49.6%4.8%0.00n/a
Septerna, Inc. SEPN$2.2 billionn/a-6.3%-44.0%13,520.1%0.00n/a
Aurinia Pharmaceuticals Inc. AUPH$2.2 billion7.1947.8%48.6%21.0%0.00n/a
Perrigo Co. plc PRGO$2.2 billionn/a-72.5%-39.4%-4.5%1.357.3%
Immunome Inc. IMNM$2.1 billionn/a-48.4%n/an/a0.00n/a
Zymeworks Inc. ZYME$2.1 billionn/a-186.6%-419.0%-69.8%0.00n/a
Vir Biotechnology, Inc. VIR$2.1 billionn/a-20.6%-69.8%1,696.0%0.00n/a
Prestige Consumer Healthcare Inc. PBH$2.0 billion13.268.0%25.0%5.1%1.07n/a
Recursion Pharmaceuticals, Inc. RXRX$2.0 billionn/a-52.5%-725.4%56.2%0.01n/a
Trulieve Cannabis Corp. TRLV$2.0 billionn/a-57.8%-25.6%-9.1%0.37n/a
Biocryst Pharmaceuticals Inc. BCRX$2.0 billionn/an/a-30.1%60.3%n/an/a
Harmony Biosciences Holdings, Inc. HRMY$1.9 billion10.9616.7%22.2%19.8%0.14n/a
Zenas BioPharma, Inc. ZBIO$1.9 billionn/an/an/an/a1.41n/a
Sarepta Therapeutics, Inc. SRPT$1.9 billionn/a-7.5%-2.5%-18.9%0.56n/a
Maze Therapeutics, Inc. MAZE$1.9 billionn/an/an/an/a0.09n/a
Novavax Inc. NVAX$1.8 billionn/an/a-21.2%-61.3%n/an/a
Agios Pharmaceuticals, Inc. AGIO$1.8 billionn/a-38.1%-297.7%214.4%0.00n/a
Stoke Therapeutics, Inc. STOK$1.7 billionn/a-69.0%-913.1%-86.3%0.00n/a
Generate Biomedicines, Inc. GENB$1.7 billionn/an/an/an/a0.00n/a
Nurix Therapeutics, Inc. NRIX$1.7 billion6.6130.5%41.3%738.8%0.000.0%
Eton Pharmaceuticals, Inc. ETON$1.6 billion37.1357.4%28.8%100.6%0.27n/a
Immunocore Holdings plc IMCR$1.6 billionn/a-7.7%-6.8%13.1%0.940.0%
Precigen, Inc. PGEN$1.6 billion128.0629.1%21.4%n/a1.12n/a
Intellia Therapeutics, Inc. NTLA$1.6 billionn/a-69.5%-821.2%-8.1%0.12n/a
Ultragenyx Pharmaceutical Inc. RARE$1.6 billionn/an/a-64.0%15.8%n/an/a
uniQure N.V. QURE$1.5 billionn/a-79.0%-1,001.7%28.0%0.17n/a
ANI Pharmaceuticals Inc. ANIP$1.5 billion13.2818.3%16.0%25.9%0.95n/a
Pacira BioSciences, Inc. PCRX$1.5 billion39.175.3%4.8%3.7%0.41n/a
Ocular Therapeutix, Inc. OCUL$1.4 billionn/a-58.0%-603.0%-8.1%0.14n/a
Nuvation Bio Inc. NUVB$1.4 billionn/a-59.6%-61.2%654.2%1.25n/a
Korsana Biosciences, Inc. KRSA$1.4 billionn/an/an/an/a0.00n/a
Taysha Gene Therapies, Inc. TSHA$1.4 billionn/a-38.6%-2,792.3%-32.3%0.13n/a
Innoviva, Inc. INVA$1.4 billion9.6017.0%38.8%12.8%0.23n/a
Phibro Animal Health Corp. PAHC$1.3 billion13.1824.6%12.5%10.1%1.761.5%
Cronos Group Inc. CRON$1.3 billion21.295.4%3.4%55.8%0.00n/a
Avalyn Pharma Inc. AVLN$1.3 billionn/an/an/an/a0.04n/a
Opko Health, Inc. OPK$1.3 billionn/a-13.3%-25.5%-21.9%0.43n/a
Mannkind Corp. MNKD$1.3 billionn/an/a-2.9%31.7%n/an/a
Inhibrx Biosciences, Inc. INBX$1.2 billionn/an/an/an/an/an/a
Omeros Corp. OMER$1.2 billionn/an/an/an/an/an/a
Amphastar Pharmaceuticals, Inc. AMPH$1.2 billion13.0112.1%18.7%3.1%0.75n/a
UroGen Pharma Ltd. URGN$1.2 billionn/an/a-12.4%159.3%n/an/a
Rapport Therapeutics, Inc. RAPP$1.2 billionn/an/an/an/a0.00n/a
Janux Therapeutics, Inc. JANX$1.1 billionn/a-11.0%-599.3%132.9%0.00n/a
Harrow, Inc. HROW$1.0 billionn/a-244.9%-1.0%21.1%19.24n/a
Cryoport, Inc. CYRX$969 millionn/a-7.8%-20.0%1.1%0.39n/a
Odyssey Therapeutics, Inc. ODTX$921 millionn/an/an/an/a0.00n/a
Monte Rosa Therapeutics, Inc. GLUE$901 millionn/a-26.4%-214.5%-61.3%0.00n/a
Syndax Pharmaceuticals Inc. SNDX$857 millionn/an/a-61.7%159.5%n/an/a
MeiraGTx Holdings plc MGTX$847 million12.6636.6%46.3%948.3%0.46n/a
Aktis Oncology, Inc. AKTS$847 millionn/an/an/an/a0.00n/a
Verastem, Inc. VSTM$794 millionn/an/an/an/a11.82n/a
Lexicon Pharmaceuticals, Inc. LXRX$791 millionn/a-38.1%-147.4%-45.6%0.32n/a
Nektar Therapeutics NKTR$759 millionn/a-17.4%-257.8%-27.2%0.00n/a
Collegium Pharmaceutical, Inc. COLL$752 million24.2012.9%15.2%7.7%3.65n/a
Rigel Pharmaceuticals Inc. RIGL$746 million2.5569.0%26.3%2.2%0.02n/a
QuidelOrtho Corp. QDEL$732 millionn/a-20.6%-4.9%-4.5%1.64n/a
Ironwood Pharmaceuticals Inc. IRWD$728 million4.89n/a62.9%18.1%n/an/a
Ardelyx, Inc. ARDX$722 millionn/a-33.8%-7.7%17.6%1.54n/a
Arbutus Biopharma Corp. ABUS$721 million4.6259.2%82.0%1,078.8%0.00n/a
Ginkgo Bioworks Holdings, Inc. DNA$718 millionn/a-69.2%-259.9%-51.5%0.00n/a
Zevra Therapeutics, Inc. ZVRA$690 million9.6032.7%60.8%75.1%0.00n/a
Wave Life Sciences, Inc. WVE$665 millionn/a-52.4%-320.9%n/a0.00n/a
Design Therapeutics, Inc. DSGN$651 millionn/a-36.6%n/an/a0.00n/a
Kura Oncology, Inc. KURA$645 millionn/a-612.8%-411.9%n/a0.20n/a
Geron Corp. GERN$636 millionn/an/an/an/a0.53n/a
Aclaris Therapeutics, Inc. ACRS$588 millionn/a-47.7%-1,414.0%-59.3%0.00n/a
Myriad Genetics Inc. MYGN$565 millionn/a-48.0%-14.3%-2.6%0.45n/a
Gyre Therapeutics, Inc. GYRE$510 millionn/a-37.5%-20.6%13.5%0.00n/a
Monopar Therapeutics MNPR$479 millionn/an/an/an/a0.00n/a
CytomX Therapeutics, Inc. CTMX$476 millionn/a-30.0%-676.5%-87.7%0.00n/a
Aquestive Therapeutics, Inc. AQST$454 millionn/an/a-114.1%12.5%n/an/a
Evolus, Inc. EOLS$450 millionn/an/a-4.8%13.9%n/an/a
Phathom Pharmaceuticals, Inc. PHAT$425 millionn/an/a-9.3%86.8%n/an/a
Puma Biotechnology, Inc. PBYI$421 million15.8519.3%13.2%-2.9%0.00n/a
Arvinas, Inc. ARVN$419 millionn/a-1.8%-12.1%-11.8%0.00n/a
CorMedix Inc. CRMD$412 million2.4840.6%47.0%n/a0.00n/a
Crescent Biopharma, Inc. CBIO$374 millionn/an/an/an/a0.00n/a
Canopy Growth Corp. CGC$276 millionn/an/a-54.2%10.7%0.38n/a
Atrium Therapeutics, Inc. RNA$143 millionn/an/an/an/an/an/a
125 companies share its SEC industry code (Pharmaceutical Preparations); the rest are the names nearest in size in its wider industry, Pharmaceutical Products, one of the Fama-French 48 industries, a published grouping of SEC industry codes.
Read moreBy market capitalisation; a click on a heading sorts by it, largest first, and a second click turns it round. Each figure is the same arithmetic as the ratio box above, on each company's own filings and latest close; a name marked * is a foreign company that files once a year, on its latest fiscal year.

The public record on VTRS

Dividends$0.48 a share over the four quarters to 30 September 2026, a 2.41% yield
Filings21 in twelve months: 14 current reports (8-K), about 6 other events; 4 results of operations; 3 material agreement; 3 officer or director change; 2 new financial obligation
Planned insider sales2 Form 144 notices in twelve months, $1.1 million; latest 25 June 2026
Options tapeput/call 0.27 by open interest at the 6 November 2026 close; the straddle prices a 5.2% move to 20 November 2026
13F holders1,039 funds reported a position for the quarter to 30 June 2026; largest FMR LLC
Insider trading2 sales and 2 purchases on Form 4 in twelve months
Congress0 House trades disclosed in six months
Short interest37.9 million shares short, 4.57 days to cover at 15 October 2026
Documentsthe 10-K, the 10-Qs, the proxy and 4 earnings press releases, each linked

Filings

FilingPeriodFiledWhere
10-Q30 September 20265 November 2026EDGAR
10-Q30 June 20266 August 2026EDGAR
10-Q31 March 20267 May 2026EDGAR
10-K31 December 202526 February 2026EDGAR
10-Q30 September 20256 November 2025EDGAR
10-Q30 June 20257 August 2025EDGAR
10-Q31 March 20258 May 2025EDGAR
10-K/A31 December 202430 April 2025EDGAR
10-K31 December 202427 February 2025EDGAR
10-Q30 September 20247 November 2024EDGAR

Reading about a stock somewhere else? Our free Chrome extension, GreekSoup Stock Ticker Lookup: Earnings, Insider Trades, 13F Holders, shows the latest quarter against a year ago, insider trades and 13F holders when you hover a $ticker such as $AAPL.